The Senate Judiciary Committee today voted 16-5 to approve the Creating and Restoring Equal Access to Equivalent Samples Act (S. 974). The AHA-supported bill would allow generic drug manufacturers facing certain anticompetitive delay tactics to bring an action in federal court for injunctive relief. More than 45 organizations, including the AHA, last week urged the committee to support the legislation to “end the anticompetitive abuses utilized by some brand-name manufacturers, help restore the balance between innovation and affordability that Congress intended, and achieve the goal of more affordable prescription drugs.” The Congressional Budget Office estimates the legislation will save $3.8 billion over 10 years.

Headline
The AHA March 24 commented to the Centers for Medicare & Medicaid Services on upcoming requirements from the Consolidated Appropriations Act of 2026…
Headline
The White House today released its national policy framework on artificial intelligence. The framework includes several recommendations for Congress…
Headline
America’s hospitals and health systems are deeply committed to providing high-quality, accessible and affordable care, AHA President and CEO Rick Pollack March…
Headline
Registration continues for the 2026 AHA Annual Membership meeting, which will be held April 19-21 in Washington, D.C. Policymakers, legislators and thought…
Headline
The AHA Feb. 27 shared recommendations on the Health Data, Technology and Interoperability: ASTP/ONC Deregulatory Actions to Unleash Prosperity proposed rule,…
Headline
The AHA provided a statement Feb. 24 for a House Ways and Means Health Subcommittee hearing titled “Advancing the Next Generation of America’s Health Care…